AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00929123 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham neural mobilization
Description: sham technique mimicking the neural mobilization which is not specific to the median nerve
Study NCT00929123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy controls
Description: People without carpal tunnel syndrome for comparison
Study NCT01495975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Transitions Tool Kit
Description: Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
Study NCT00857883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1521498 or placebo
Description: GSK1521498 is a mu-opioid receptor inverse agonist
Study NCT00857883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1521498 or placebo
Description: GSK1521498 is a mu-opioid receptor inverse agonist
Study NCT01592682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smokefree counseling
Description: Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
Study NCT00946361 — intervention group
Intervention type: OTHER
Intervention: Examinations
Description: Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
Study NCT00808483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking skill training program
Description: 12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
Study NCT03439059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Sedentary Behaviour Group
Description: Participants will be prompted to perform 10min of light physical activity (>1.5 METS) 3x/day for 6 weeks
Study NCT01976676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate
Study NCT01976676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic Acid
Study NCT00722332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaGam B
Description: Hepatitis B Immunoglobulin
Study NCT02680535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuroShell particle infusion
Description: Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
Study NCT03920787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic Combi
Description: Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
Study NCT03920787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules every day for 1 month
Study NCT04439149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-beta Inhibitor GSK2636771
Description: Given PO
Study NCT04470271 — intervention group
Intervention type: OTHER
Intervention: Patients with hepatitis C lost follow up
Description: Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
Study NCT02903641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized information
Description: During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening.
Study NCT02903641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labeled cash transfer
Description: Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
Study NCT03080454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Doublestim
Description: PathMaker MyoRegulator device
Study NCT03080454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal Doublestim
Description: PathMaker MyoRegulator device
Study NCT03500575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photopheresis
Description: • Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
Study NCT00843531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5 mg/day PO (oral)
Study NCT00843531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100 mg/day (oral)
Study NCT01772160 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
Study NCT04391491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuregulin-1β level in plasma
Description: Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
Study NCT04680130 — intervention group
Intervention type: DRUG
Intervention: C-11 PiB
Description: Completing PET scan looking for amyloid protein
Study NCT04680130 — intervention group
Intervention type: DRUG
Intervention: AV1451 Tau
Description: Completing PET scan looking for tau protein
Study NCT04680130 — intervention group
Intervention type: DRUG
Intervention: C-11 ER176
Description: Completing PET scan looking for neuroinflammation
Study NCT02570360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
Study NCT02570360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment-as-usual
Description: The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
Study NCT02460107 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Study NCT02460107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT01076231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Study NCT01076231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01076231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01076231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT05012657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Partial
Description: The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
Study NCT00142610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin
Description: This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
Study NCT00142610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin
Description: This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
Study NCT01123850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copios
Description: Bone Void Filler
Study NCT05007210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal massage therapy
Description: Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
Study NCT01601314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started.
Study NCT01601314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started.
Study NCT03491956 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DFPP
Description: Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
Study NCT01501929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study NCT01501929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study NCT01501929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive measurement of Cardiac Output (CO)
Description: Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
Study NCT01501929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial cell collection
Description: We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
Study NCT01501929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular perfusion assessment using Definity
Description: Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
Study NCT02664220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Description: Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister.
Study NCT02664220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No irrigation
Description: Patients allocated to the control group will not undergo intra-abdominal irrigation.
Study NCT00512824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low calcium milk of 180 ml
Description: twice daily for 24 weeks
Study NCT00512824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular milk of 180 ml
Description: twice daily for 24 weeks
Study NCT00512824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular milk of 180 ml + probiotics
Description: twice daily for 24 weeks
Study NCT00108524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate ketogenic diet
Description: A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
Study NCT00108524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: In addition to the low fat diet, Orlistat is taken 3 times daily.
Study NCT00108524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytolacca decandra
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytolacca decandra
Description: Treatment of bruxism
Study NCT03293199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube drainage
Description: In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
Study NCT03293199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive needle aspiration
Description: In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
Study NCT03140254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Study NCT03140254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride
Study NCT03140254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03077178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Description: Geriatric assessment, questionnaire assessment
Study NCT04434066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
Study NCT03631173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical og radiological intervention, antibiotics
Description: Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
Study NCT02762994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Study NCT02762994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01306019 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
Description: Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
Study NCT00565513 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood test
Description: cord blood and maternal milk test
Study NCT01995331 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide,cyclosporine A
Description: Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was >1×109/L.
Study NCT02351635 — intervention group
Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
Study NCT03525340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
Study NCT02232334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Osteopathic Manual Treatment
Description: subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
Study NCT01354327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 3 tablets / day during 4 months
Study NCT01354327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets / day during 4 months